Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Posters
Publications
Contact Us
Contact Us
Email Alerts
Media
Recent Posts
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
Categories
Company News
Media
Uncategorized
Videos
30 Sep 2021
Amplia Therapeutics welcomes Garvan paper highlighting benefits of FAK inhibition in pancreatic cancer models
Read More
30 Sep 2021
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer
Read More
30 Sep 2021
Breakthrough research lowers pancreatic cancer’s resistance to chemo
Read More
20 Sep 2021
Proactive | Interview with Dr John Lambert
Read More
26 Jul 2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Read More
26 Jul 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
21 Jul 2021
Amplia Therapeutics returns successful phase one trial results
Read More
19 Jul 2021
Garvan's June Seminar: The Power of Personalised Medicine
Read More
30 Jun 2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Read More
28 Jun 2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Read More
09 Oct 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
09 Oct 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
1
2